LYSMD3

Across TCGA pan-cancer cohorts, LYSMD3 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated LYSMD3 data layer compared with 27 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher LYSMD3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated LYSMD3 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

CESC, UCEC, and PRAD are the cancer types where LYSMD3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	DFS	Median	III,IV	0.091	0.728	<.001	24	view →
UCEC	DFS	Median	All	0.958	0.622	.027	20	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

LYSMD3–CESC (DFS)

Open the CESC breakdown →